CARDIX THERAPEUTICS

Clinical Trials

 

The improvement of cardiac function and the treatment of chronic bradycardia remains an essential unsolved issue. Currently, no regulatory-approved drug of this type is available in the U.S or the world.

CARDIX Therapeutics is developing a patent drug to improve cardiac function by increasing heart rate and cardiac output. The new drug provides an alternative option to a pacemaker for treating chronic bradycardia and improving cardiac function.

 

U.S. Clinical Trials (New Drug Development for Treatment of Bradycardia)

The current clinical Phase IIA study, "An Exploratory Safety and Efficacy Study of CARDIX-101 for the treatment of Chronic Bradycardia," is a multi-center clinical study. See clinicaltrials.gov (NCT 05117346).

 

Clinical Sites: There are three clinical sites. One is in San Diego, CA, and the others are in Miami, FL. It may increase to other locations in the USA.

 

Treatment Regimen: A clinical study period of 14±2-days is planned for each enrollment of patients.

 

Route of Administration: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.

 

We are currently recruiting participants for three Clinical sites

(one in San Diego, CA, and two in Miami, FL)

please fill out the form below if you are interested: